Europe acute schizophrenia treatment Market - 2024-2031

Overview

Europe Acute Schizophrenia Treatment Market reached US$ 2.4 billion in 2023 and is expected to reach US$ 3.5 billion by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Acute schizophrenia treatment aims to manage and alleviate severe symptoms of the complex mental health disorder, characterized by delusions, hallucinations, disorganized thinking, and cognitive impairment. It typically involves a combination of antipsychotic medications, with first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) commonly prescribed.

Supportive therapies like psychotherapy, cognitive behavioral therapy, and social support are also crucial for comprehensive care. Effective acute treatment not only addresses immediate symptoms but also sets the foundation for long-term management and recovery, enhancing the overall quality of life for individuals with schizophrenia.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of schizophrenia

Rise in the prevalence of schizophrenia in region especially in countries like UK is one of the major driving factors for the market to grow during the forecast period. For instance, according to NHS, Schizophrenia affects 1 in 100 people and occurs Europe, affecting both men and women. It is a major illness, with around 220,000 people treated in the UK by the NHS. Sufferers have a 5 to 10% chance of dying within ten years of diagnosis, which is two and a half times higher than the general population.

Schizophrenia is most common in late teens and early twenties, with women experiencing it slightly later. It runs in families, with a parent or sibling with the illness being more likely to suffer from it themselves. Schizophrenia is not caused by poor parenting or childhood adversity.

Complications associated with the drugs

Antipsychotic medications for acute schizophrenia can cause various side effects, including extrapyramidal symptoms, weight gain, diabetes, metabolic syndrome, sedation, dry mouth, blurred vision, orthostatic hypotension, and severe effects like neuroleptic malignant syndrome or agranulocytosis. Regular monitoring and medication adjustments are crucial for effective management of these side effects, ensuring the patient's safety and well-being.

Segment Analysis

The Europe acute schizophrenia treatment market is segmented based on drug type, route of administration, end-user and country.

The antipsychotics from the drug type segment accounted for approximately 54.1% of the Europe acute schizophrenia treatment market share

The antipsychotics from the drug type segment accounted for approximately 54.1%. Antipsychotics are essential in treating acute schizophrenia by managing symptoms and stabilizing the condition. They target neurotransmitter systems, particularly dopamine receptors, which are often dysregulated in the disorder. By modulating dopamine activity, they can reduce symptoms like delusions, hallucinations, and agitation.

For instance, in January 2023, Newron Pharmaceuticals reported promising results from its international, randomized, open-label, rater-blinded study of evenamide as an add-on to an antipsychotic in patients with moderate to severe treatment-resistant schizophrenia (TRS). The study, which lasted for 30 weeks, involved 85 of the 100 patients who completed the 30-week treatment period with evenamide, indicating promising results for the treatment of TRS patients who were not responding to their current antipsychotic medication.

Geographical Analysis

France is estimated to hold about 38.4% of the total market share throughout the forecast period

France is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, FDA approvals, expansions, increased healthcare infrastructure, and others that help the country to grow during the forecast period.

For instance, in April 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd and MedinCell announced that the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone. Therapeutic blood concentrations are reached within 6-24 hours of a single dose

Market Segmentation

By Drug Type

• Antipsychotics
  • First-Generation Antipsychotics (FGAs)
  • Second-Generation Antipsychotics (SGAs)
• Adjunctive Medications

By Route of Administration

• Oral
• Injectable
• Intravenous (IV)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Competitive Landscape

The major Europe players in the market include Roche Holding AG, Novartis AG, Pfizer Inc, Johnson & Johnson, Eli Lilly and Company, AbbVie Inc, Otsuka Pharmaceutical Co., Ltd, AstraZeneca plc, H. Lundbeck A/S, Mylan N.V among others.

Key Developments

• In July 2024, Celon Pharma, a Polish pharmaceutical company, believed its experimental treatment for acute schizophrenia could eventually achieve annual sales in the billions of dollars. The drug achieved favorable results in the second phase of clinical studies, showing high efficacy and good patient tolerance. Celon Pharma's founder, Maciej Wieczorek, believes the company can reach a billion-dollar product, even with typical antipsychotics currently under patent costing $200 to $1,000 per month in therapy.

Why Purchase the Report?

• To visualize the Europe acute schizophrenia treatment market segmentation based on drug type, route of administration, distribution channel, and country as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the acute schizophrenia treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Europe acute schizophrenia treatment market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies